Tirzepatide

Overview

Tirzepatide is the first approved drug to simultaneously activate two separate metabolic receptors — GIP and GLP-1 — and the clinical trial data behind it is some of the most striking in the history of obesity medicine. In the SURMOUNT-1 trial, patients on the highest dose lost an average of 22.5% of their body weight over 72 weeks.[1] For context, that's a 250-pound person losing roughly 56 pounds. That's a big number.

It's sold under two brand names by Eli Lilly: Mounjaro for type 2 diabetes (FDA-approved May 2022) and Zepbound for chronic weight management (FDA-approved November 2023). The molecule is identical — a 39-amino acid synthetic peptide administered as a once-weekly subcutaneous injection. The brand name just depends on what your doctor is prescribing it for.

If you've been following the GLP-1 space, tirzepatide sits one step above semaglutide in terms of both mechanism complexity and observed efficacy. Whether that difference matters for you specifically depends on your metabolic profile, your tolerance for GI side effects, and frankly, your insurance situation.

Mechanism of Action

Simultaneous GIP receptor and GLP-1 receptor agonism

Two receptors. That's the short version. Here's what each one actually does.

GLP-1 receptors (glucagon-like peptide-1) are found throughout the body — in the pancreas, the brain, the stomach, and the heart. When tirzepatide activates GLP-1 receptors in the pancreas, it triggers insulin release in proportion to how much glucose is in your blood. This is the "glucose-dependent" part of its mechanism — it stimulates insulin only when blood sugar is elevated, which is why hypoglycemia (dangerously low blood sugar) is rare compared to older diabetes drugs. GLP-1 receptor activation in the brain suppresses appetite signals and increases the sense of fullness. In the stomach, it slows gastric emptying — food moves through more slowly, which extends satiety after meals.

GIP receptors (glucose-dependent insulinotropic polypeptide) work through a complementary pathway. GIP is actually the first incretin hormone discovered — it was identified before GLP-1 — but it fell out of favor for drug development because people with type 2 diabetes show a blunted GIP response, which led researchers to assume it wasn't useful therapeutically. Tirzepatide's clinical results suggest that assumption was wrong. GIP receptor activation appears to amplify the insulin-secreting effects of GLP-1 signaling, may improve fat cell metabolism directly, and could reduce some of the GI side effects that come with pure GLP-1 agonism.[2] The exact mechanism for that last point is still being worked out — but patients on tirzepatide do report somewhat better GI tolerability than equivalent doses of semaglutide in some head-to-head comparisons.

The 39-amino acid structure of tirzepatide includes a C20 fatty diacid chain attached via a linker, which is what gives it the ~5-day half-life and allows once-weekly dosing. Without that modification, the peptide would be cleared from the body within minutes.

What the Evidence Shows

SURMOUNT-1 (obesity, no T2D): The primary obesity trial enrolled adults with a BMI of 30 or higher (or 27+ with a weight-related comorbidity) but without type 2 diabetes.[1] At 72 weeks, mean weight loss was approximately 15% at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg, compared to 2.4% for placebo. Roughly 57% of participants on 15 mg lost at least 20% of their body weight. That figure — more than half of patients losing a fifth of their body weight — had no precedent in pharmaceutical weight management before this trial.

SURPASS-2 (T2D, head-to-head vs. semaglutide): Over 40 weeks in patients with type 2 diabetes, all three tirzepatide doses (5 mg, 10 mg, 15 mg) outperformed semaglutide 1 mg on both HbA1c reduction and weight loss.[2] The 15 mg dose reduced HbA1c by a mean of 2.46 percentage points — moving many patients from poorly controlled to well-controlled diabetes by that metric alone. Weight loss at 15 mg averaged 12.4 kg (about 27 lbs), versus 6.2 kg for semaglutide.

SURMOUNT-4 (weight maintenance): After an initial 36-week open-label period where all participants received tirzepatide, the trial randomized patients to continue tirzepatide or switch to placebo for 52 more weeks.[3] Continued tirzepatide produced an additional ~5.5% weight loss; placebo led to regain of roughly two-thirds of the initial weight lost. The trial confirmed what the mechanism predicts: stopping the drug reverses most of the effect.

SURMOUNT-OSA (obstructive sleep apnea): A 2024 trial published in the New England Journal of Medicine tested tirzepatide specifically in adults with moderate-to-severe obstructive sleep apnea and obesity.[4] Tirzepatide significantly reduced the apnea-hypopnea index (AHI, the standard measure of sleep apnea severity) compared to placebo. This was notable enough that the FDA approved tirzepatide (Zepbound) for obstructive sleep apnea in adults with obesity in June 2024 — making it the first drug approved for that indication.

Side Effects
Tirzepatide's side effect profile follows the same general pattern as the GLP-1 class, but the dual mechanism does appear to shift the distribution slightly.

If you experience severe or persistent abdominal pain, signs of an allergic reaction (difficulty breathing, facial swelling), or vision changes, contact your provider the same day — don't wait for your next scheduled appointment.